In line with this, it was recently reported that NSCLCs with KRAS mutation transiently respond to a first-generation TKI, whereas they escape prolonged suppression through the activation of other ERBB family members while the second-generation TKI afatinib persistently suppresses tumor growth via broad inhibitory effects on the ERBB family [40, 41]. This evidence concerns the gene EGFR and neoplasm.